AL
RIGL icon

Airain Ltd’s Rigel Pharmaceuticals RIGL Stock Holding History

Airain Ltd’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-2,708
Closed -$97K – 1053
2015
Q1 		$97K Sell
2,708
-2,294
-46% -$62.9K 0.01% 761
2014
Q4 		$114K Buy
+5,002
New +$101K 0.01% 641

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Airain Ltd's RIGL Position: Q2 2015 in Review

Airain Ltd sold out of Rigel Pharmaceuticals (RIGL) in Q2 2015, closing a stake of 2,708 shares — an estimated $97K sold.

Airain Ltd first reported a position in RIGL in Q4 2014 and held it in 2 quarters. The position peaked at $114K in Q4 2014. 123 funds tracked by Wall St. Rank hold RIGL as of Q2 2015.

  • Airain Ltd reported no remaining Rigel Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Airain Ltd sold 2,708 Rigel Pharmaceuticals shares in Q2 2015, an estimated $97K.
  • Airain Ltd first reported a position in Rigel Pharmaceuticals in Q4 2014 and held it in 2 quarters.
  • Airain Ltd's Rigel Pharmaceuticals position peaked at $114K in Q4 2014.
  • 123 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2015.

Based on Airain Ltd's 13F filing for Q2 2015, filed 5 Aug 2015.